Currently out of the existing stock ratings of Gil Blum, 376 are a BUY (96.91%), 9 are a HOLD (2.32%), 3 are a SELL (0.77%).

Gil Blum

Work Performance Price Targets & Ratings Chart

Analyst Gil Blum, currently employed at NEEDHAM, carries an average stock price target met ratio of 26.11% that have a potential upside of 69.11% achieved within 144 days. Previously, Gil Blum worked at TRUIST.

Gil Blum’s has documented 739 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on FOLD, Amicus Therapeutics at 18-Sep-2025.

Wall Street Analyst Gil Blum

Analyst best performing recommendations are on CTIC (CTI BIOPHARMA CORP).
The best stock recommendation documented was for CELC (CELCUITY LLC) at 6/30/2025. The price target of $29 was fulfilled within 28 days with a profit of $15.65 (117.23%) receiving and performance score of 41.87.

Average potential price target upside

of $49.71 (56.24%) on SRPT (SAREPTA THERAPEUTICS).
of $30.9 (60.39%) on CRSP (CRISPR THERAPEUTICS AG).
of $12.96 (126.75%) on CELC (CELCUITY LLC).

AVRO AVROBIO GBIO Generation Bio Co TSHA Taysha Gene Therapies FOLD Amicus Therapeutics AUTL Autolus Therapeutics Ltd RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics AGLE Aeglea Bio Therapeutics GTHX G1 Therapeutics NRIX Nurix Therapeutics NXTC NextCure MREO Mereo BioPharma Group PLC ADR IMAB I-Mab SELB Selecta Biosciences STTK Shattuck Labs GMDA Gamida Cell Ltd CTIC CTi Biopharma Corp ACLX Arcellx GERN Geron CELC Celcuity LLC CRSP Crispr Therapeutics AG NKTX Nkarta RXRX Recursion Pharmaceuticals IMCR Immunocore Holdings Ltd FATE Fate Therapeutics TCRX Tscan Therapeutics ARTV Artiva Biotherapeutics, Common Stock RNAC Cartesian Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Uy Ear (MIZUHO)